rs182506368 — SLC39A4 SLC39A4 p.Ala99Thr

Pathogenic missense variant in the ZIP4 intestinal zinc transporter causing hereditary acrodermatitis enteropathica when homozygous; heterozygotes are asymptomatic carriers with near-normal zinc absorption

See your personal result for SLC39A4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SLC39A4 and the Zinc Gateway — A Pathogenic Missense in ZIP4

Your body cannot synthesize zinc — every atom must enter through the intestinal wall. The protein that makes this possible is ZIP411 ZIP4
Zrt/Irt-like Protein 4, encoded by SLC39A4 on chromosome 8q24.3; the dominant apical zinc importer on the brush border of duodenal and jejunal enterocytes. When both copies of SLC39A4 carry loss-of-function mutations, dietary zinc simply cannot cross the gut wall. The result — hereditary acrodermatitis enteropathica (AE)22 acrodermatitis enteropathica (AE)
A rare autosomal recessive disorder of zinc malabsorption presenting with the classic triad of periorificial and acral dermatitis, chronic diarrhea, and alopecia; incidence approximately 1 in 500,000 newborns globally — is universally fatal without treatment and completely manageable with it.

This missense variant falls within the extracellular N-terminal domain of ZIP4. The substitution alters a conserved residue at codon 99 (alanine to threonine), disrupting protein folding in the region responsible for zinc coordination and trafficking to the apical membrane. Heterozygous carriers have one functional SLC39A4 copy and absorb zinc adequately in normal conditions; their zinc status is clinically indistinguishable from non-carriers.

The Mechanism

ZIP4 is an eight-transmembrane zinc transporter with a large extracellular N-terminal ectodomain essential for function. Under zinc-replete conditions, the ectodomain is proteolytically shed as a regulatory response that limits further zinc import — a feedback loop that AE-associated mutations disrupt33 AE-associated mutations disrupt
Kambe & Andrews, Mol Cell Biol, 2009 by preventing normal cleavage. Under zinc-deficient conditions, full-length ZIP4 is rapidly recruited to the apical membrane to maximize absorption.

Functional studies of AE-causing missense mutations show two dominant mechanisms depending on mutation location. Variants near the histidine-rich and proline-rich subdomains of the ectodomain cause ER retention with immature glycosylation — the protein misfolds and never reaches the cell surface44 ER retention with immature glycosylation — the protein misfolds and never reaches the cell surface
Kuliyev et al., J Biol Chem, 2021. Transmembrane domain variants such as P200L and G539R reach the plasma membrane but lose zinc-responsive endocytosis, reducing zinc uptake Vmax to approximately 30% of wild-type55 30% of wild-type
Wang et al., Hum Mol Genet, 2004. Either mechanism produces functional zinc malabsorption sufficient to cause AE when homozygous.

The Evidence

Küry et al. 2002 (Nature Genetics)66 Küry et al. 2002 (Nature Genetics) identified SLC39A4 as the causative gene for AE through linkage analysis and mutational screening of eight affected families. Subsequent cataloguing by Schmitt et al. 2009 (Human Mutation)77 Schmitt et al. 2009 (Human Mutation) expanded the known mutation spectrum to 31 variants across the entire gene. Missense mutations are the most frequent class. Genotype-phenotype correlation is poor — identical mutations can present with variable severity — suggesting modifier genes or environmental factors modulate the clinical picture.

AE presents within the first 4–10 weeks of life in formula-fed infants and later in breastfed infants (human milk contains a ligand that facilitates zinc absorption despite reduced ZIP4 activity). Without treatment, progressive zinc deficiency causes immune failure, growth retardation, photosensitivity, and neurological deterioration.

Practical Actions

For homozygous individuals (TT genotype), lifelong zinc supplementation is the established treatment. Oral zinc gluconate, sulfate, or acetate at 5–10 mg elemental zinc per kg/day corrects the deficiency acutely; maintenance dosing of 1–2 mg/kg/day is used long-term. Response is typically rapid — skin lesions and diarrhea resolve within days of initiating supplementation.

For heterozygous carriers (CT genotype), zinc absorption is adequate under normal dietary conditions. No supplementation is required unless serum zinc falls below reference range, which may occur during pregnancy, illness, or restrictive diets that increase zinc demand.

Interactions

SLC39A4 pathogenic variants interact in compound heterozygosity. A person who carries this allele on one chromosome and a second SLC39A4 loss-of-function variant (such as rs121434288, rs121434290, or rs121434291) on the other chromosome has functional AE — effectively the same as being homozygous for one variant. The full zinc supplementation protocol applies to confirmed compound heterozygotes.

Zinc competes for intestinal absorption with copper, iron, and calcium. High-dose zinc therapy can deplete copper over time; monitoring of serum copper and ceruloplasmin is recommended during long-term high-dose zinc replacement.

Nutrient Interactions

zinc reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

CC Non-Carrier Normal

Standard ZIP4 zinc transporter function

You carry two copies of the common allele at this SLC39A4 position. Your ZIP4 zinc transporter functions normally, and zinc absorption from the intestine proceeds through the standard pathway. This variant does not affect your zinc status or risk of acrodermatitis enteropathica. Approximately 99.8% of people share this genotype.

CT Carrier Carrier

Heterozygous carrier of one SLC39A4 pathogenic allele

With one functional SLC39A4 allele, your intestinal zinc absorption is expected to be adequate under normal dietary conditions. Published data do not support a consistently measurable reduction in serum zinc in confirmed SLC39A4 heterozygotes under typical dietary conditions.

The primary clinical relevance of carrier status is reproductive: if both biological parents carry SLC39A4 pathogenic alleles, each pregnancy has a 25% probability of producing a homozygous child with acrodermatitis enteropathica, a 50% probability of producing a carrier, and a 25% probability of producing a non-carrier. Genetic counseling is recommended if your partner's SLC39A4 status is unknown and you are planning a family.

Under conditions of elevated zinc demand (pregnancy, lactation, illness, restrictive diet) or impaired zinc intake, carriers may benefit from monitoring serum zinc levels. This is a precautionary measure, not a treatment requirement.

TT Homozygous Homozygous

Homozygous for SLC39A4 pathogenic variant — acrodermatitis enteropathica

Hereditary acrodermatitis enteropathica presents in infancy, typically within the first 4–10 weeks in formula-fed infants or later in breastfed infants (human milk contains a zinc-ligand that partially bypasses the ZIP4 defect). Untreated, the hallmark triad is periorificial and acral dermatitis (rash around the mouth, eyes, and genitals, and on the hands and feet), chronic diarrhea, and alopecia. Immune failure, growth retardation, and neurological symptoms follow with prolonged deficiency.

Zinc supplementation produces a dramatic and rapid clinical response — skin lesions and diarrhea typically resolve within days. Dosing is established: 5–10 mg/kg/day of elemental zinc initially, tapering to 1–2 mg/kg/day for maintenance after clinical remission. All forms (zinc gluconate, sulfate, acetate) are effective; zinc gluconate has superior gastrointestinal tolerability at high doses. Treatment must be lifelong; stopping supplementation causes rapid relapse.

Long-term high-dose zinc therapy requires copper monitoring: zinc induces intestinal metallothionein, which preferentially sequesters copper and can deplete serum copper over months to years. Periodic serum copper and ceruloplasmin measurement is standard practice in AE management.